NIH #1R01AG091781-01A1
Epac1 Signaling Promotes Retinal Neuronal Injury During Tauopathy
Active
- Amount
- $617K
- Period
- 2026-06-15 → 2031-03-31
- PIs
- 2
- Est. capacity / PI
- ~5 students
Awarded at UNIVERSITY OF TEXAS MED BR GALVESTON
NIH #5R35GM134744-07
Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
Active
- Amount
- $660K
- Period
- 2020-01-01 → 2030-03-31
- PIs
- 1
- Est. capacity / PI
- ~4 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #2R35GM134744-06
Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
Active
- Amount
- $660K
- Period
- 2020-01-01 → 2030-03-31
- PIs
- 1
- Est. capacity / PI
- ~4 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01DK136462-02
Significance of Epac signaling in renal Na+handling and hypertension
Active
- Amount
- $679K
- Period
- 2024-08-19 → 2028-06-30
- PIs
- 2
- Est. capacity / PI
- ~2 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #1R01DK136462-01A1
Significance of Epac signaling in renal Na+handling and hypertension
Active
- Amount
- $679K
- Period
- 2024-08-19 → 2028-06-30
- PIs
- 2
- Est. capacity / PI
- ~2 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R01EY033319-04
Epac1 as a novel therapeutic target for diabetic retinopathy
Active
- Amount
- $506K
- Period
- 2022-09-01 → 2027-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R01EY033319-03
Epac1 as a novel therapeutic target for diabetic retinopathy
Active
- Amount
- $506K
- Period
- 2022-09-01 → 2027-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R01EY033319-02
Epac1 as a novel therapeutic target for diabetic retinopathy
Active
- Amount
- $506K
- Period
- 2022-09-01 → 2027-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #1R01EY033319-01A1
Epac1 as a novel therapeutic target for diabetic retinopathy
Active
- Amount
- $515K
- Period
- 2022-09-01 → 2027-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R01DK132286-04
Mutual reinforcement between somatic mutations and transcription factors in clonal hematopoiesis
Active
- Amount
- $436K
- Period
- 2023-03-01 → 2026-12-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
NIH #5R01DK132286-03
Mutual reinforcement between somatic mutations and transcription factors in clonal hematopoiesis
Active
- Amount
- $437K
- Period
- 2023-03-01 → 2026-12-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
NIH #5R01DK132286-02
Mutual reinforcement between somatic mutations and transcription factors in clonal hematopoiesis
Active
- Amount
- $422K
- Period
- 2023-03-01 → 2026-12-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
NIH #1R01DK132286-01A1
Mutual reinforcement between somatic mutations and transcription factors in clonal hematopoiesis
Active
- Amount
- $445K
- Period
- 2023-03-01 → 2026-12-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
NIH #3R01EY033319-03S1
Epac1 as a novel therapeutic target for diabetic retinopathy
- Amount
- $40K
- Period
- 2025-07-01 → 2026-06-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R21CA277152-02
Preclinical studies of non-nucleoside DNMT3A/3B inhibitors
- Amount
- $189K
- Period
- 2023-12-19 → 2025-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1R21CA277152-01A1
Preclinical studies of non-nucleoside DNMT3A/3B inhibitors
- Amount
- $227K
- Period
- 2023-12-19 → 2025-11-30
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R35GM134744-05
Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
- Amount
- $585K
- Period
- 2020-01-01 → 2025-03-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R35GM134744-04
Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
- Amount
- $585K
- Period
- 2020-01-01 → 2024-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #3R35GM134744-04S1
Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
- Amount
- $250K
- Period
- 2020-01-01 → 2024-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R35GM134744-03
Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
- Amount
- $585K
- Period
- 2020-01-01 → 2024-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R35GM134744-02
Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
- Amount
- $585K
- Period
- 2020-01-01 → 2024-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1R35GM134744-01
Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms
- Amount
- $585K
- Period
- 2020-01-01 → 2024-12-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #1R56DK136462-01
Significance of Epac signaling in renal Na+ handling and hypertension
- Amount
- $150K
- Period
- 2023-08-15 → 2024-07-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5P30CA016672-47
25 Cancer Genetics and Epigenetics
- Amount
- $19K
- Period
- 1996-08-28 → 2024-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P30CA016672-46
25 Cancer Genetics and Epigenetics
- Amount
- $19K
- Period
- 1996-08-28 → 2024-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5P30CA016672-45
25 Cancer Genetics and Epigenetics
- Amount
- $19K
- Period
- 1996-08-28 → 2024-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R35GM122536-05
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics
- Amount
- $429K
- Period
- 2017-07-01 → 2023-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #3R35GM122536-03S1
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics
- Amount
- $48K
- Period
- 2017-07-01 → 2022-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R35GM122536-04
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics
- Amount
- $429K
- Period
- 2017-07-01 → 2022-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R35GM122536-03
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics
- Amount
- $429K
- Period
- 2017-07-01 → 2022-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R35GM122536-02
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics
- Amount
- $429K
- Period
- 2017-07-01 → 2022-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #1R35GM122536-01
Exchange Protein directly Activated by cAMP (EPAC): Structure, Function and Therapeutics
- Amount
- $115K
- Period
- 2017-07-01 → 2022-06-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R01AI111464-05
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
- Amount
- $1.2M
- Period
- 2014-04-10 → 2021-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #7R01GM049245-24
DNA Methylation: Structures, Functions and Regulation
- Amount
- $497K
- Period
- 1993-04-01 → 2020-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01GM114306-05
Histone Lysine deMethylation: Structures, Inhibitions and Mechanisms
- Amount
- $295K
- Period
- 2015-04-01 → 2020-03-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01GM066170-15
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
- Amount
- $373K
- Period
- 2003-05-01 → 2019-04-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R01AI111464-04
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
- Amount
- $1.2M
- Period
- 2014-04-10 → 2019-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #7R01GM114306-04
Histone Lysine deMethylation: Structures, Inhibitions and Mechanisms
- Amount
- $310K
- Period
- 2015-04-01 → 2019-03-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TX MD ANDERSON CAN CTR
NIH #5R01AI111464-03
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
- Amount
- $1.3M
- Period
- 2014-04-10 → 2019-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R01GM114306-02
Histone Lysine deMethylation: Structures, Inhibitions and Mechanisms
- Amount
- $289K
- Period
- 2015-04-01 → 2019-03-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at EMORY UNIVERSITY
NIH #5R01AI111464-02
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
- Amount
- $1.3M
- Period
- 2014-04-10 → 2019-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #1R01GM114306-01
Histone Lysine deMethylation: Structures, Inhibitions and Mechanisms
- Amount
- $303K
- Period
- 2015-04-01 → 2019-03-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at EMORY UNIVERSITY
NIH #1R01AI111464-01
Preclinical Development of Novel Rickettsiosis Therapeutics Targeting EPAC1
- Amount
- $1.5M
- Period
- 2014-04-10 → 2019-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #3R01GM049245-22S1
DNA Methylation: Structures, Functions and Regulation
- Amount
- $75K
- Period
- 1993-04-01 → 2018-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at EMORY UNIVERSITY
NIH #5R01GM049245-22
DNA Methylation: Structures, Functions and Regulation
- Amount
- $388K
- Period
- 1993-04-01 → 2018-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at EMORY UNIVERSITY
NIH #5R01GM066170-14
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
- Amount
- $373K
- Period
- 2003-05-01 → 2018-04-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #5R01GM066170-13
Epac/cAMP-GEF, A Novel Intracellular cAMP Receptor
- Amount
- $373K
- Period
- 2003-05-01 → 2018-04-30
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
NIH #3R01GM049245-23S1
DNA Methylation: Structures, Functions and Regulation
- Amount
- $138K
- Period
- 1993-04-01 → 2017-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at EMORY UNIVERSITY
NIH #5R01GM049245-23
DNA Methylation: Structures, Functions and Regulation
- Amount
- $388K
- Period
- 1993-04-01 → 2017-07-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at EMORY UNIVERSITY
NIH #5R01GM106218-03
Novel Pharmacological Probes Targeting Exchange Proteins Activated by cAMP (EPAC)
- Amount
- $308K
- Period
- 2013-04-01 → 2017-03-31
- PIs
- 2
- Est. capacity / PI
- ~0 students
Awarded at UNIVERSITY OF TEXAS MED BR GALVESTON